Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infectious Disease Transmission, Vertical | 11 | 2012 | 76 | 1.330 |
Why?
|
| HIV Infections | 17 | 2016 | 976 | 1.110 |
Why?
|
| HIV-1 | 15 | 2016 | 725 | 1.080 |
Why?
|
| Pregnancy Complications, Infectious | 8 | 2007 | 65 | 0.820 |
Why?
|
| Nevirapine | 5 | 2003 | 8 | 0.660 |
Why?
|
| Anti-HIV Agents | 7 | 2005 | 156 | 0.540 |
Why?
|
| Herpesvirus 4, Human | 5 | 2010 | 198 | 0.500 |
Why?
|
| Infectious Mononucleosis | 3 | 2010 | 34 | 0.430 |
Why?
|
| Reverse Transcriptase Inhibitors | 4 | 2003 | 28 | 0.350 |
Why?
|
| AIDS Vaccines | 3 | 2012 | 72 | 0.330 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2016 | 94 | 0.230 |
Why?
|
| Milk, Human | 1 | 2006 | 91 | 0.230 |
Why?
|
| Drug Resistance, Viral | 3 | 2004 | 156 | 0.230 |
Why?
|
| RNA, Viral | 6 | 2016 | 276 | 0.210 |
Why?
|
| Pediatrics | 1 | 2006 | 261 | 0.200 |
Why?
|
| Infant | 8 | 2021 | 1664 | 0.200 |
Why?
|
| Virus Replication | 3 | 2016 | 324 | 0.200 |
Why?
|
| Anti-Retroviral Agents | 3 | 2016 | 76 | 0.190 |
Why?
|
| Pregnancy | 9 | 2007 | 2370 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2002 | 137 | 0.180 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 2 | 2012 | 60 | 0.180 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2010 | 184 | 0.170 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2021 | 54 | 0.170 |
Why?
|
| Infant, Newborn | 8 | 2021 | 1375 | 0.160 |
Why?
|
| src Homology Domains | 1 | 1999 | 21 | 0.150 |
Why?
|
| Genetic Linkage | 1 | 1999 | 96 | 0.150 |
Why?
|
| X Chromosome | 1 | 1999 | 46 | 0.150 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1999 | 39 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 356 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 1999 | 343 | 0.130 |
Why?
|
| Adolescent | 8 | 2010 | 6305 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2010 | 679 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2021 | 291 | 0.120 |
Why?
|
| Female | 17 | 2016 | 33382 | 0.120 |
Why?
|
| Antibodies, Viral | 2 | 2010 | 329 | 0.120 |
Why?
|
| Humans | 26 | 2021 | 64283 | 0.110 |
Why?
|
| Severe Acute Respiratory Syndrome | 2 | 2005 | 23 | 0.110 |
Why?
|
| DNA, Viral | 1 | 2016 | 234 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 544 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 1999 | 709 | 0.110 |
Why?
|
| Developing Countries | 2 | 2005 | 94 | 0.100 |
Why?
|
| Adult | 13 | 2011 | 17134 | 0.100 |
Why?
|
| Influenza A virus | 2 | 2010 | 124 | 0.090 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2012 | 134 | 0.090 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2011 | 30 | 0.090 |
Why?
|
| Pharyngitis | 1 | 2010 | 13 | 0.080 |
Why?
|
| Streptococcus pyogenes | 1 | 2010 | 31 | 0.080 |
Why?
|
| Viral Load | 5 | 2016 | 233 | 0.080 |
Why?
|
| Streptococcal Infections | 1 | 2010 | 80 | 0.080 |
Why?
|
| AIDS Serodiagnosis | 1 | 2009 | 19 | 0.080 |
Why?
|
| Molecular Sequence Data | 4 | 2011 | 1999 | 0.070 |
Why?
|
| Fowlpox virus | 1 | 2008 | 4 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 181 | 0.070 |
Why?
|
| Mutation | 5 | 2005 | 2633 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 984 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2010 | 329 | 0.070 |
Why?
|
| Europe | 2 | 2007 | 197 | 0.060 |
Why?
|
| Africa South of the Sahara | 1 | 2006 | 21 | 0.060 |
Why?
|
| Phylogeny | 2 | 2011 | 385 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2016 | 2019 | 0.060 |
Why?
|
| Orthomyxoviridae | 1 | 2005 | 26 | 0.060 |
Why?
|
| Monkey Diseases | 1 | 2005 | 7 | 0.060 |
Why?
|
| Callithrix | 1 | 2005 | 21 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2005 | 203 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2005 | 96 | 0.050 |
Why?
|
| Membrane Glycoproteins | 2 | 2005 | 671 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 705 | 0.050 |
Why?
|
| Viral Envelope Proteins | 1 | 2005 | 103 | 0.050 |
Why?
|
| Developed Countries | 1 | 2003 | 16 | 0.050 |
Why?
|
| Bahamas | 1 | 2003 | 22 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2003 | 73 | 0.050 |
Why?
|
| Brazil | 1 | 2003 | 100 | 0.050 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2002 | 11 | 0.050 |
Why?
|
| Gene Products, vpr | 1 | 2002 | 7 | 0.050 |
Why?
|
| Pneumonia | 1 | 2005 | 291 | 0.050 |
Why?
|
| HLA-A2 Antigen | 3 | 2010 | 64 | 0.050 |
Why?
|
| Prevalence | 1 | 2006 | 1407 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2003 | 645 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2002 | 197 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2005 | 634 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2003 | 744 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2003 | 153 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2008 | 93 | 0.040 |
Why?
|
| Male | 6 | 2016 | 30322 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2003 | 266 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2016 | 245 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2002 | 247 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 870 | 0.040 |
Why?
|
| Postpartum Period | 1 | 2002 | 196 | 0.040 |
Why?
|
| Neonatal Screening | 1 | 2021 | 102 | 0.040 |
Why?
|
| Monocytes | 1 | 2002 | 357 | 0.040 |
Why?
|
| Signaling Lymphocytic Activation Molecule Associated Protein | 1 | 1999 | 3 | 0.040 |
Why?
|
| Base Sequence | 1 | 2002 | 1335 | 0.040 |
Why?
|
| Child | 3 | 2009 | 4583 | 0.040 |
Why?
|
| Interferon-gamma | 3 | 2008 | 576 | 0.040 |
Why?
|
| Neutralization Tests | 2 | 2012 | 127 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2021 | 184 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 386 | 0.040 |
Why?
|
| United States | 3 | 2007 | 7923 | 0.030 |
Why?
|
| Oligopeptides | 2 | 2010 | 135 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 71 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2008 | 668 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 115 | 0.030 |
Why?
|
| Massachusetts | 1 | 2021 | 2096 | 0.030 |
Why?
|
| HIV Long-Term Survivors | 2 | 2005 | 8 | 0.030 |
Why?
|
| Epitopes | 2 | 2005 | 292 | 0.030 |
Why?
|
| Cesarean Section | 2 | 2007 | 104 | 0.030 |
Why?
|
| Animals | 3 | 2006 | 20967 | 0.030 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 2 | 2003 | 19 | 0.020 |
Why?
|
| T-Lymphocytes | 2 | 2008 | 1019 | 0.020 |
Why?
|
| Labor, Obstetric | 2 | 2003 | 38 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1272 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2004 | 467 | 0.020 |
Why?
|
| Immunologic Memory | 2 | 2005 | 290 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2009 | 3318 | 0.020 |
Why?
|
| Lymphocyte Activation | 2 | 2005 | 761 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2011 | 59 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 1597 | 0.020 |
Why?
|
| Clone Cells | 1 | 2010 | 116 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2010 | 134 | 0.020 |
Why?
|
| Viral Matrix Proteins | 1 | 2010 | 50 | 0.020 |
Why?
|
| Immunodominant Epitopes | 1 | 2010 | 57 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2016 | 5696 | 0.020 |
Why?
|
| Time Factors | 2 | 2009 | 3725 | 0.020 |
Why?
|
| Lung | 2 | 2005 | 964 | 0.020 |
Why?
|
| Young Adult | 2 | 2010 | 4781 | 0.020 |
Why?
|
| Protein Binding | 2 | 2005 | 1619 | 0.020 |
Why?
|
| CD4-CD8 Ratio | 1 | 2008 | 16 | 0.020 |
Why?
|
| Vaccinia | 1 | 2008 | 32 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2010 | 417 | 0.020 |
Why?
|
| Gene Products, gag | 1 | 2008 | 67 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2008 | 78 | 0.020 |
Why?
|
| HIV Antibodies | 1 | 2008 | 148 | 0.020 |
Why?
|
| Abortion, Spontaneous | 1 | 2007 | 31 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 668 | 0.020 |
Why?
|
| Gestational Age | 1 | 2007 | 191 | 0.020 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2005 | 11 | 0.020 |
Why?
|
| Chemokine CCL4 | 1 | 2005 | 14 | 0.020 |
Why?
|
| Mothers | 1 | 2009 | 276 | 0.020 |
Why?
|
| Genes, MHC Class I | 1 | 2005 | 27 | 0.010 |
Why?
|
| K562 Cells | 1 | 2005 | 58 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 195 | 0.010 |
Why?
|
| Gene Products, vif | 1 | 2005 | 9 | 0.010 |
Why?
|
| vif Gene Products, Human Immunodeficiency Virus | 1 | 2005 | 13 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 2005 | 52 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2005 | 296 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 153 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 458 | 0.010 |
Why?
|
| Cytokines | 1 | 2008 | 945 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 1683 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2005 | 229 | 0.010 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2005 | 116 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2005 | 220 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 869 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2005 | 417 | 0.010 |
Why?
|
| Myocardium | 1 | 2005 | 288 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 412 | 0.010 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2004 | 96 | 0.010 |
Why?
|
| Lamivudine | 1 | 2003 | 7 | 0.010 |
Why?
|
| Heart | 1 | 2005 | 288 | 0.010 |
Why?
|
| Zidovudine | 1 | 2003 | 12 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2003 | 73 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 891 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2003 | 40 | 0.010 |
Why?
|
| Genes, vpr | 1 | 2002 | 4 | 0.010 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 1 | 2002 | 5 | 0.010 |
Why?
|
| Delivery, Obstetric | 1 | 2003 | 53 | 0.010 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 2002 | 15 | 0.010 |
Why?
|
| Perforin | 1 | 2002 | 31 | 0.010 |
Why?
|
| Leukocyte Common Antigens | 1 | 2002 | 59 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 98 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 99 | 0.010 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2002 | 38 | 0.010 |
Why?
|
| B7-1 Antigen | 1 | 2002 | 74 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2002 | 141 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 590 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 299 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2003 | 221 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 191 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 455 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 490 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1002 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 1297 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 671 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2003 | 312 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2003 | 241 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2007 | 2605 | 0.010 |
Why?
|
| Alleles | 1 | 2002 | 449 | 0.010 |
Why?
|
| Cell Line | 1 | 2005 | 2057 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 1270 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 2177 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2002 | 501 | 0.010 |
Why?
|
| Inflammation | 1 | 2005 | 1163 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 785 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2238 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 5341 | 0.010 |
Why?
|
| Apoptosis | 1 | 2002 | 1095 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2003 | 1541 | 0.010 |
Why?
|
| Middle Aged | 1 | 2010 | 17921 | 0.010 |
Why?
|
| Mice | 1 | 2005 | 11004 | 0.010 |
Why?
|